Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Study of Apetrol ES

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is a healty male between 20 and 55 years old.~* In a ± 20% than ideal body weight. \[ideal body weight(kg) = height(cm)-100) x 0.9 (Broca's rule)~* Subjects who are considered to be suitable in conducting the clinical trial in serum test, hematology test, hemato-chemical test, urine test and 12-ECG result.~* Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~* Agrees to use an adequate means of contraception during clinical trials~* Subject who has voluntarily decided to participate in this clinical trial and consented in writing.~Exclusion Criteria:~* Is allergic against Megestrol acetate or other drugs (Aspirin, NSAIDs, Antibiotics, etc.) or against foods, or has an clinically serious allergic history.~* Subjects who have present condition or past history of any disease involving liver, kidney, nervous system, immune system, respiratory system, or endocrine system; hematologic and oncologic disease; cardiovascular disease; or psychiatric disorder (mood disorder, obsessive-compulsive disorder, etc. that may affect ADME of investigational medicinal products.~* In the vital signs measured in sitting position at the screening visit, subjects who have hypertension desease(a systolic blood pressure of ≥ 150 mmHg or a diastolic blood pressure of ≥ 100 mmHg).~* Diabetic patients or the patients who are abnormal of impaired glucose tolerance.~* The patients who have a history of Arterial Embolism.~* The patients who have a history of adrenal insufficiency like hypotension or nausea or vertigo or asthenia or etc.~* Subjects who have a history of drug abuse or shown positive reaction to drugs that may be abused from a urine drug screening~* Subjects who took any specialized drug or an herbal medication within 2 weeks before the date of first administration or took any over the counter (OTC) drug within 1 week (however, they may be included as subjects if appropriate depending on the investigator's discretion)~* Subjects who had whole blood donation within 2 months or component blood donation within 1 month before the clinical trial.~* Subjects who have abnormal diets that may affect ADME of investigational medicinal products.~* Subjects who have been drinking extremely alcohol and caffeine (more than caffeine 5 cups/day, soju 3 cups/day, beer 3 cups/day, liquors 2 cups/day, 10 cigarettes/day) or can't refrain from drinking during the clinical trial period.~* Subjects who had administration a barbiturates within 1 month before the date of first drug administration~* Subjects who already participated in other clinical trials within 2 months before this clinical trial.~* Subjects who are considered to be unsuitable in conducting the clinical trial for other reason at the principal investigator's discretionary judgment

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Megace : fed (Type: EXPERIMENTAL): Megace / Apetrol ES : comparator / test, fed
- Apetrol ES : fed (Type: EXPERIMENTAL): Apetrol ES / Megace : test / comparator, fed, cross-over
- Megace : fasting (Type: EXPERIMENTAL): Megace / Apetrol ES : comparator / test, fasting
- Apetrol ES : fasting (Type: EXPERIMENTAL): Apetrol ES / Megace : test / comparator, fasting, cross-over

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete